Saturday 17 October 2026
Export OM’s income statement to Excel — free account
Outset Medical, Inc.
Outset Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $119.5 million, up 5.09% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 6.73%, free cash flow fell 90.5% and total debt rose 4.20%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.94
0.14
−3.43%
Follow OM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.68 | 0.60 | 0.47 | 2.09 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.35) | (5.49) | (5.93) | (39.73) | |
P/B ratio |
0.83 | 0.63 | 0.44 | 1.81 | |
Price to Tangible BV |
0.83 | 0.63 | 0.44 | 1.81 | |
EV/Sales |
0.28 | 0.10 | (0.13) | 1.41 | |
EV/EBITDA |
0.00 | 0.00 | 0.24 | 0.00 | |
EV/Operating CF |
(0.86) | (0.35) | 0.33 | (3.17) | |
EV/FCF |
(0.85) | (0.35) | 0.32 | (3.13) | |
Quick Ratio |
4.02 | 4.84 | 5.24 | 5.65 | |
Current Ratio |
5.19 | 6.29 | 6.67 | 7.09 | |
Net Debt/EBITDA |
3.14 | 3.61 | 4.21 | 5.37 | |
Debt/Assets |
40.76% | 38.88% | 36.39% | 34.45% | |
Debt/Equity |
1.03 | 0.87 | 0.76 | 0.67 | |
Asset Turnover |
0.44 | 0.43 | 0.44 | 0.42 | |
Operating CF/Net income |
0.54 | 0.68 | 0.49 | 0.35 | |
Capex/Depreciation |
(0.46) | (0.17) | (0.65) | (0.50) | |
Interest Coverage |
(4.55) | (5.02) | (5.12) | (4.55) | |
Research and Development Expense of Revenue |
17.23% | 20.16% | 17.51% | 18.27% | |
Selling, General and Administrative Expense of Revenue |
74.31% | 83.97% | 85.91% | 74.84% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8.52% | 12.39% | 14.07% | 17.26% | |
Graham Net Nets |
1.02 | 1.40 | 2.01 | 0.52 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(94.68%) | (108.33%) | (183.02%) | (92.40%) | |
Free Cash Flow Yield |
(48.34%) | (48.54%) | (83.51%) | (21.47%) | |
Revenue per Share |
1.70 | 1.52 | 1.90 | 1.66 | |
Operating CF per Share |
(0.52) | (0.70) | (0.63) | (0.36) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.52) | (0.70) | (0.64) | (0.36) | |
Cash per Share |
7.91 | 8.53 | 11.11 | 10.05 | |
Shareholders Equity per Share |
5.17 | 6.08 | 8.35 | 8.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.17 | 6.08 | 8.35 | 8.01 | |
Free Cash Flow |
(9.75) | (12.91) | (9.74) | (6.48) | |
Working Capital |
183.96 | 199.10 | 213.25 | 227.92 | |
Capital Expenditures |
(0.11) | (0.06) | (0.22) | (0.16) | |
Net Current Asset Value |
81.80 | 98.94 | 113.34 | 130.48 | |
EV/EBIT |
0.00 | 0.00 | 0.23 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
32.06 | 31.11 | 31.97 | 33.61 | |
Average Payables |
2.95 | 1.31 | 2.21 | 3.01 | |
Average Inventory |
49.78 | 52.71 | 53.50 | 55.36 | |
Average Assets |
265.59 | 275.33 | 270.15 | 285.07 | |
Average Common Equity |
123.64 | 138.86 | 76.89 | 93.17 |
Columns are period end dates